Breakthrough in Bladder Cancer Treatment! Lin Tianxin and Chen Xu’s Team at Sun Yat-sen University First to Demonstrate Safety and Preliminary Efficacy of Intravesical Disitamab Vedotin in HER2-Positive High-Risk Non-Muscle-Invasive Bladder Cancer

Breakthrough in Bladder Cancer Treatment! Lin Tianxin and Chen Xu’s Team at Sun Yat-sen University First to Demonstrate Safety and Preliminary Efficacy of Intravesical Disitamab Vedotin in HER2-Positive High-Risk Non-Muscle-Invasive Bladder Cancer

2025.08.01
A research team led by Professor Lin Tianxin and Professor Chen Xu from the Sun Yat-sen Memorial Hospital of Sun Yat-sen University has published clinical trial results in the prestigious journal MedComm, titled “Intravesical Disitamab Vedotin (RC48) for HER2-Expressing High-Risk Non-Muscle-Invasive Bladder Cancer: A Single-Arm, Dose–Escalation Phase I Trial Study.” This marks the world’s first clinical study to evaluate the intravesical administration of the HER2-targeted antibody–drug conjugate (ADC) disitamab vedotin (RC48) in patients with HER2-positive high-risk non-muscle-invasive bladder cancer (HR-NMIBC). The study offers a novel bladder-sparing strategy for patients who are unresponsive or intolerant to Bacillus Calmette-Guérin (BCG) therapy.
Exclusive Interview with EHA President | Professor Martin Dreyling: Unmissable Breakthroughs in Myeloma, Leukemia, and Lymphoma at EHA 2025

Exclusive Interview with EHA President | Professor Martin Dreyling: Unmissable Breakthroughs in Myeloma, Leukemia, and Lymphoma at EHA 2025

2025.07.31
The 2025 European Hematology Association (EHA) Annual Congress was successfully held from June 12 to 15 in Milan, Italy. Marking the 30th anniversary of the EHA, this year’s congress stood out as a major milestone, drawing over 15,000 experts and scholars from around the world with its global impact and groundbreaking research highlights. During the event, Oncology Frontier – Hematology Frontier had the privilege of speaking with Professor Martin Dreyling, Chair of the EHA 2025 Scientific Program Committee (SPC) and a professor at LMU Munich, to explore the most transformative scientific advances presented at the meeting.
EHA Highlight | Professor Evangelos Terpos: A Comprehensive Upgrade in MM Management—What’s New in the 2025 EHA-EMN Clinical Guidelines?

EHA Highlight | Professor Evangelos Terpos: A Comprehensive Upgrade in MM Management—What’s New in the 2025 EHA-EMN Clinical Guidelines?

2025.07.31
At the 2025 Annual Congress of the European Hematology Association (EHA), the much-anticipated updated EHA-EMN clinical practice guidelines for multiple myeloma (MM) were officially released. Covering key areas such as diagnostic assessment, risk stratification, treatment pathways, and follow-up management, the new guidelines provide more forward-thinking and practical guidance for clinical implementation.
Professor Xiaoyu Zhu: Double-Negative T Cells — A New Breakthrough in Acute Myeloid Leukemia Therapy | 9th CSCO Hematologic Oncology Congress

Professor Xiaoyu Zhu: Double-Negative T Cells — A New Breakthrough in Acute Myeloid Leukemia Therapy | 9th CSCO Hematologic Oncology Congress

2025.07.30
In the height of summer, Harbin—known as the “Ice City”—welcomed a gathering of scientific minds. From July 11 to 13, 2025, the 9th Annual Hematologic Oncology Congress of the Chinese Society of Clinical Oncology (CSCO) was held in Harbin. The congress brought together top experts from China and abroad to discuss advancements in leukemia, lymphoma, multiple myeloma, and other hematologic diseases, spanning basic research, novel drug development, precision medicine, and clinical translation. Acute myeloid leukemia (AML) remains one of the most challenging diseases in clinical hematology, urgently requiring innovative breakthroughs. At the conference, Professor Xiaoyu Zhu from the First Affiliated Hospital of the University of Science and Technology of China (Anhui Provincial Hospital) presented exciting findings on “Basic and Translational Research on Double-Negative T Cells for AML Treatment.” In an exclusive interview with Oncology Frontier – Hematology Frontier, Professor Zhu further elaborated on the latest progress in this cutting-edge field.